(HealthDay)—Mavyret (glecaprevir and pibrentasvir) tablets are now approved to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17 years, the U.S. Food and Drug Administration announced yesterday. The FDA approved Mavyret to treat HCV in adults in 2017. This new approval marks the first treatment option for all HCV […]